COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 6 of these applications claim priority to application 61/494,710, filed Jun 8, 2011. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,195,145 | Method for Treating Fibrosis Using Sirna and a Retinoid-Lipid Drug Carrier In force · Medium confidence UsedRemaining | Nitto Denko Corporation | In force | Medium confidence | ||
| US 9,408,864 | Composition for Regenerating Normal Tissue from Fibrotic Tissue In force · High confidence | Nitto Denko Corporation | In force | High confidence | ||
| US 9,011,903 | Cationic Lipids for Therapeutic Agent Delivery Formulations In force · High confidence | Nitto Denko Corporation | In force | High confidence | ||
| US 9,242,001 | Cationic Lipids for Therapeutic Agent Delivery Formulations In force · High confidence | Nitto Denko Corporation | In force | High confidence | ||
| US 9,393,315 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY In force · High confidence | Nitto Denko Corporation | In force | High confidence | ||
| US 9,456,984 | Method for Treating Fibrosis Using Sirna and a Retinoid-Lipid Drug Carrier In force · High confidence | Nitto Denko Corporation | In force | High confidence | ||
| US 9,963,424 | Cationic Lipids for Therapeutic Agent Delivery Formulations In force · High confidence | Nitto Denko Corporation | In force | High confidence | ||
| US 10,000,447 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY In force · High confidence | Nitto Denko Corporation | In force | High confidence | ||
| US 10,100,004 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY In force · High confidence | Nitto Denko Corporation | In force | High confidence | ||
| US 10,196,637 | Retinoid-Lipid Drug Carrier In force · Medium confidence | Nitto Denko Corporation | In force | Medium confidence | ||
| 25 more records in this group · Pro | ||||||
10 of 35 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 35, including 9 expired.
13 of these are in force and held by Nitto Denko Corporation.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.